Ensysce Biosciences Inc (ENSC) USD0.0001
Sell:$2.05Buy:$2.10
$0.03
(1.46%)
- This stock can be held in a
Stocks and Shares ISA$0.03
(1.46%)$0.03
(1.46%)Company Information
About this company
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company develops solutions for severe pain relief while reducing the potential for opioid misuse, abuse, and overdose. Its pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection (TAAP) platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant (MPAR) platform. Its lead product, PF614, is a TAAP extended-release oxycodone and a potential analgesic to treat severe pain. Its second product, PF614-MPAR, is to treat severe pain with the added benefit of oral overdose protection, is a combination product of the TAAP prodrug PF614 with a trypsin inhibitor. Additionally, nafamostat, which is an ingredient in its overdose protection combination products, is also being developed for the intended purpose of treating infection and pulmonary lung diseases.
Key people
Key facts
- EPICENSC
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINUS2936025046
- Market cap$3.37m
- Employees7
- Shares in issue1.64m
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.